https://doi.org/10.55788/e4fa4eb4
Depression is a common comorbidity in MS and is associated with increased disease activity and disability. Dr Kaarina Kowalec (University of Manitoba, Canada) phrased the research question as follows: âIs the cumulative genetic burden for depression associated with MS disease activity and disability worsening?â To measure the genetic burden for depression, the researchers used the PGS, which reflects the number of inherited common genetic variants, weighted by their effect sizes. Using genetic variants also means that reverse causation as an explanation for any association between the PGS and outcomes can be excluded.
Dr Kolwalec and colleagues used a case-control study design, using samples from 3 cohorts from Canada (IMID study), USA (CombiRx trial), and Sweden (SMSReg) with extensive longitudinal phenotypes. They included 3,420 relapsing-onset MS cases of European genetic ancestry, with a median follow-up of 3â5 years.
âWe found that a higher depression PGS was associated with relapse risk,â Dr Kowalec said. âEvery 1 standard-deviation increase in the PGS was associated with a 23% increased hazard of relapse in the meta-analysisâ (incidence rate ratio 1.23; 95% CI 1.01â1.50). In the US cohort, which was the only clinical trial cohort, a higher genetic burden for depression was also significantly associated with relapse risk (HR 2.20; 95% CI 1.35â3.60) and confirmed Expanded Disability Status Scale (EDSS) worsening (HR 1.51; 95% CI 1.03â2.22).
- Manouchehrinia A, et al. The association between depression polygenicity and disease activity and disability worsening in multiple sclerosis. Abstract O132, ECTRIMS 2024, 18â20 September, Copenhagen, Denmark.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« More comorbidity is associated with worse clinical outcomes in MS Next Article
Transfer of ocrelizumab into breastmilk is negligible »
« More comorbidity is associated with worse clinical outcomes in MS Next Article
Transfer of ocrelizumab into breastmilk is negligible »
Table of Contents: ECTRIMS 2024
Featured articles
Revised McDonald criteria allow earlier and more precise MS diagnosis
Approaches to RIS and MS converge
Diagnosis, Biomarkers, and Phenotypes
Revised McDonald criteria allow earlier and more precise MS diagnosis
Approaches to RIS and MS converge
AI versus clinicians: who diagnoses MS faster and better?
Blood markers predict MS progression
Gut microbiota modulate inflammation and cortical damage
Risk factors and importance of persistent PIRA
Vitamin D supplementation in progressive MS should be medically supervised
Treatment: Strategies
Encouraging real-world results of AHSCT to treat aggressive MS
CAR T-cell therapy in MS: in its infancy but highly anticipated
B cell-tailored dosing of ocrelizumab shows good results
First-line moderate-efficacy DMTs show similar efficacy
Treatment: Trials
Tolebrutinib slows disability worsening in relapsing MS
Frexalimab shows favourable safety and efficacy in OLE
Good safety of ozanimod over up to 8 years of treatment
Tolebrutinib slows disability in non-relapsing SPMS
High-dose simvastatin does not slow disability progression in SPMS
Pregnancy and Comorbidity Risks
Transfer of ocrelizumab into breastmilk is negligible
High genetic burden for depression associated with MS disease activity
More comorbidity is associated with worse clinical outcomes in MS
NMOSD/MOGAD
Ineffective response to EBV in MS not seen in similar diseases
Comparative effectiveness and safety of DMTs in NMOSD
Age, time, and treatment determine relapse risk in MOGAD
Related Articles
April 18, 2022
Late-onset alcohol abuse may signal dementia
August 18, 2021
Neural base of persistent hyposmia after COVID-19
March 15, 2019
Tremor
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com